NCT02602704View on ClinicalTrials.gov

Effectiveness of Bazedoxifene for Prevention of Glucocorticoid-induced Bone Loss in RA Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

December 29, 2015

Primary Completion Date

October 11, 2017

Study Completion Date

December 1, 2018

Conditions
Arthritis, Rheumatoid
Interventions
DRUG

Bazedoxifene

Bazedoxifene 20mg/day (Viviant) for 48 weeks

DRUG

Calcium/Vit D

Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 \* 2/day) for 48 weeks

Trial Locations (1)

04763

Hanyang University, Seoul

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Hanyang University

OTHER

NCT02602704 - Effectiveness of Bazedoxifene for Prevention of Glucocorticoid-induced Bone Loss in RA Patients | Biotech Hunter | Biotech Hunter